Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:
Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. This quarter, the company hopes to follow up those positive results with the readout of a second, Phase 3 study.
Create a display name to comment
This name will appear with your comment